Anti-Amyloid Therapies for Alzheimer's Disease and the Amyloid Cascade Hypothesis.

More detailed results were presented at the Alzheimer’s Association International Conference (AAIC) in July–August 2022 and confirmed that differences in the cognitive primary and in all the clinical secondary endpoints, as well as biomarker outcomes, did not reach statistical significance, although there was a trend favouring crenezumab [ 81 ].

also in 111,027 other papers

Yet, the evidence that the amount of Aβ plaques in the AD brain did not correlate either with disease severity or cognitive impairment, along with the observation that a highly significant percentage of cognitively unimpaired elderly people (up to 40%) showed abnormal amyloid plaque burden, led researchers to modify the original ACH.

also in 132,142 other papers